This live session took place on September 20, 2018

Rapid growth in the Chinese cardiovascular and orthopedic market and large foreseeable opportunities have attracted significant investment from both multinational competitors and local players alike over the past decade. However, rising health care expenditure has forced the Chinese government to implement cost-cutting initiatives, such as the Made in China 2025 program, introducing hospital guidelines to purchase more domestic products, and amendments to provincial reimbursement policies, which has significantly altered the competitive landscape in some cardiovascular and orthopedic device markets.

This webinar answered:

  • What is the impact of recent government policies on the cardiovascular and orthopedic device industry?
  • How has the competitive landscape changed in recent years in key cardiovascular and orthopedic device markets?
  • What are some of the strategies employed by domestic companies to gain market share?
  • What are the strengths and weaknesses of domestic and traditional multinational companies in the Chinese cardiovascular and orthopedic markets?

Please complete the form below view the webinar recording

Mainland China’s anticipated biosimilar boom – potential and key drivers of the market

View Now